|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
|
20373368 |
2010 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The adiponutrin risk variant is a common genetic determinant of progressive liver fibrosis.
|
21168459 |
2011 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analysis, the predictive variables for advanced liver fibrosis were age (≥60) (P=0.005), sex (female) (P=0.004) and rs 738409 PNPLA3 polymorphism (P=0.01); body mass index (BMI) and LFC were not associated with liver fibrosis.
|
21745307 |
2011 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
PNPLA3 p.148M/M genotype was negatively associated with SVR and early viral kinetics independently of steatosis, albeit only in difficult-to-cure G1/4 patients with advanced fibrosis, whereas stratification for the p.148M/M PNPLA3 genotype unmasked an association between IL28B CC genotype and more severe liver fibrosis.
|
22530607 |
2012 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was designed to assess the contribution of these SNPs to disease progression in patients with chronic hepatitis C. The study enrolled 220 Japanese patients with chronic hepatitis C. Three SNPs, -1195 COX-2, PNPLA3 and IL28B (rs8099917), were genotyped in order to analyze their association with hepatic fibrosis and inflammation.
|
22863264 |
2012 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allelic variation (rs738409C→G) in adiponutrin (patatin-like phospholipase domain-containing protein 3, PNPLA3) has been associated with hepatic steatosis and liver fibrosis.
|
23418085 |
2013 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 variant was associated with more severe features of steatohepatitis: steatosis (P < 0.001), lobular inflammation (P < 0.001), and ballooning (P = 0.002), but not with liver fibrosis, anthropometry, or insulin resistance.
|
23512881 |
2013 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The common PNPLA3 (adiponutrin) variant, p.I148M, was identified as a genetic determinant of liver fibrosis.
|
24152445 |
2013 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to determine the association between PNPLA3 and liver fibrosis severity, HCC risk, and HCC prognosis among patients with liver disease.
|
24445574 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conversely, this enzymatic activity is markedly reduced with purified PNPLA3 148M, a common mutation robustly associated with liver fibrosis and hepatocellular carcinoma development.
|
24670599 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To perform a comprehensive study on independent modulators of liver fibrosis progression and determinants of portal pressure considering immune status, insulin resistance (IR), serum 25-hydroxyvitamin D (25(OH)D) levels, genetic variants of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and interleukin 28B (IL28B) in a thoroughly documented cohort of HIV/hepatitis C-coinfected (HIV/HCV) patients.
|
24905495 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.
|
24978903 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 rs738409 polymorphism is common and may confer a significant risk of NAFLD and advanced liver fibrosis in the Korean population.
|
25069572 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 I148M sequence variant favors hepatic lipid accumulation and confers susceptibility to hepatic fibrosis and hepatocellular carcinoma.
|
25171251 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, the common I148M variant of the PNPLA3 gene influencing hepatic lipid metabolism influences HCC risk independently of its effect on the progression of liver fibrosis.
|
25278690 |
2014 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When patients were grouped according to their diabetes status, the PNPLA3 genetic variants were associated with advanced liver fibrosis in diabetic patients only, but not in non-diabetic patients.
|
25457210 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we briefly highlight future research that may elucidate the specific mechanisms of the PNPLA3 I148M variant in fibrogenesis, which, in turn, provides a theoretical foundation and valuable experimental data for the clinical management of nonalcoholic fatty liver fibrosis.
|
25624712 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with both CHB and NAFLD, these genotypes of PNPLA3 polymorphisms were associated with increased susceptibility to nonalcoholic steatohepatitis (NASH) (NAFLD activity score ≥ 3; P = 0.01-0.03) and liver fibrosis (> 1 Metavir grading; P = 0.01-0.04).
|
26229402 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genetic variant in adiponutrin (PNPLA3) gene, rs738409 C/G, is associated with steatosis, severity, and progression of liver fibrosis in CHC patients, and predicts treatment outcome in difficult-to-cure HCV-infected patients with advanced fibrosis.
|
26389885 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
|
26419236 |
2016 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced liver fibrosis was neither associated with PNPLA3 (p = 0.253) nor IL28B-genotype (p = 0.628), but with HCV-GT3 (p = 0.003), higher BMI (p = 0.008) and higher age (p = 0.007).
|
26599080 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients.
|
26760234 |
2016 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
|
26765961 |
2016 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide evidence to indicate that PNPLA3-mediated retinol release may protect against liver fibrosis by inducing a specific signature of proteins involved in extracellular matrix remodelling.
|
27742777 |
2016 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of minor allele (G) of PNPLA3 was also associated with moderate/severe steatosis (≥33%) both in patients with (OR: 2.405 [CI95%: 1.220-4.744], P=0.011) and without MetS (OR: 2.481 [CI95%: 1.172-5.250], P=0.018), but was only associated with NASH (OR: 2.002 [CI95%: 1.062-3.772], P=0.032) and liver fibrosis (OR: 2.646 [CI95%: 1.299-5.389], P=0.007) in patients without MetS.
|
27908400 |
2017 |